Condition: Androgenetic Alopecia · Sponsor: Pelage Pharmaceuticals, Inc.
The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK. Part 1 of the trial is the randomized controlled portion that will focus on safety and PK following 28 days of blinded treatment administration with either PP405 or vehicle control. Part 2 of the trial is an open-label extension that will validate the results of Part 1 with 3 months of treatment administration.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| California Dermatology & Clinical Research Institute | Encinitas, California, United States | — |
| Clinical Trials Research Institute | Thousand Oaks, California, United States | — |
| Dawes Fretzin Clinical Research Group, LLC | Indianapolis, Indiana, United States | — |
| Minnesota Clinical Study Center | New Brighton, Minnesota, United States | — |
| DermResearch | Austin, Texas, United States | — |
| Stride Clinical Research LLC | Sugar Land, Texas, United States | — |
| Jordan Valley Dermatology Center | South Jordan, Utah, United States | — |
| Virginia Clinical Research, Inc. | Norfolk, Virginia, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06393452